NCT00129740View on ClinicalTrials.gov

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

PHASE2CompletedINTERVENTIONAL

Enrollment

148

Participants

Timeline

Start Date

June 27, 2005

Primary Completion Date

July 11, 2018

Study Completion Date

July 11, 2018

Conditions

Leukemia, Myelogenous, Chronic

Interventions

DRUG

Nilotinib

400 mg orally twice daily

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER